{'fraction_non_alphanumeric': 0.01751592356687898, 'fraction_numerical': 0.0015923566878980893, 'mean_word_length': 5.691489361702128, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Danazol treatment of severely symptomatic fibrocystic breast disease and long‐term follow‐up—the Hjørring project

Abstract. The purpose of the investigation was to study various aspects of danazol treatment in patients with fibro‐cystic breast disease and pronounced mastodynia. To qualify for inclusion, the patients in this study had to have a mammographically confirmed prominent glandular structure and/or severe cystic breast disease, associated with pronounced cyclical mastodynia lasting at least one week per menstrual bycle for more than 6 months. They also had to be premenopausal and not undergoing hormonal therapy.